Literature DB >> 1955176

Severe chronic active hepatitis (autoimmune type) mimicked by coinfection of hepatitis C and human immunodeficiency viruses.

L Berk1, S W Schalm, R A Heijtink.   

Abstract

Severe chronic active hepatitis, defined as the presence of a fivefold increase in serum aminotransferases and a twofold rise in gamma globulin for at least 10 weeks, is considered a progressive immunological liver disease requiring corticosteroid treatment, particularly when serum autoantibodies and a severe lymphoplasmacellular periportal infiltrate are found in the liver biopsy specimen. A 38 year old man who fulfilled the criteria for severe chronic active hepatitis is described. His sex, his homosexuality, and the presence of antibodies against HIV, however, led to the suspicion of a coinfection with hepatitis C virus (HCV) rather than autoimmune disease. The rapid and complete response to alpha interferon treatment and a recently available positive antibody test for HCV supported this view. These findings indicate that a HCV related chronic active hepatitis can present as the severe autoimmune type of chronic active hepatitis. Moreover, as in HBV infection, the response to treatment differs from that of autoimmune severe chronic active hepatitis.

Entities:  

Mesh:

Year:  1991        PMID: 1955176      PMCID: PMC1379385          DOI: 10.1136/gut.32.10.1198

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  12 in total

1.  Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report.

Authors:  J H Hoofnagle; K D Mullen; D B Jones; V Rustgi; A Di Bisceglie; M Peters; J G Waggoner; Y Park; E A Jones
Journal:  N Engl J Med       Date:  1986-12-18       Impact factor: 91.245

2.  Controlled trial of prednisone and azathioprine in active chronic hepatitis.

Authors:  I M Murray-Lyon; R B Stern; R Williams
Journal:  Lancet       Date:  1973-04-07       Impact factor: 79.321

3.  Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis.

Authors:  R D Soloway; W H Summerskill; A H Baggenstoss; M G Geall; G L Gitnićk; I R Elveback; L J Schoenfield
Journal:  Gastroenterology       Date:  1972-11       Impact factor: 22.682

4.  Controlled prospective trial of corticosteroid therapy in active chronic hepatitis.

Authors:  G C Cook; R Mulligan; S Sherlock
Journal:  Q J Med       Date:  1971-04

5.  Classification and treatment of chronic active liver disease.

Authors:  M G Geall; L J Schoenfield; W H Summerskill
Journal:  Gastroenterology       Date:  1968-12       Impact factor: 22.682

6.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

7.  Direct polyclonal activation of human B lymphocytes by the acquired immune deficiency syndrome virus.

Authors:  S M Schnittman; H C Lane; S E Higgins; T Folks; A S Fauci
Journal:  Science       Date:  1986-09-05       Impact factor: 47.728

8.  Responses to treatment can differentiate chronic active liver disease with cholangitic features from the primary biliary cirrhosis syndrome.

Authors:  A P Geubel; A H Baggenstoss; W H Summerskill
Journal:  Gastroenterology       Date:  1976-09       Impact factor: 22.682

9.  Current concepts. Primary sclerosing cholangitis.

Authors:  N F LaRusso; R H Wiesner; J Ludwig; R L MacCarty
Journal:  N Engl J Med       Date:  1984-04-05       Impact factor: 91.245

10.  Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result?

Authors:  I G McFarlane; H M Smith; P J Johnson; G P Bray; D Vergani; R Williams
Journal:  Lancet       Date:  1990-03-31       Impact factor: 79.321

View more
  3 in total

Review 1.  Autoimmune hepatitis. Evolving concepts and treatment strategies.

Authors:  A J Czaja
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

2.  Hepatic histology of patients with HIV infection and chronic hepatitis C treated with interferon.

Authors:  R Boldorini; P Viganò; G Monga; M Nebuloni; A Cargnel; G Gubertini; G Migliaretti; G Costanzi
Journal:  J Clin Pathol       Date:  1997-09       Impact factor: 3.411

3.  microRNA-143-3p attenuated development of hepatic fibrosis in autoimmune hepatitis through regulation of TAK1 phosphorylation.

Authors:  Hanxiao Tu; Dazhi Chen; Chao Cai; Qianjing Du; Hongwei Lin; Tongtong Pan; Lina Sheng; Yuedong Xu; Teng Teng; Jingjing Tu; Zhuo Lin; Xiaodong Wang; Rui Wang; Lanman Xu; Yongping Chen
Journal:  J Cell Mol Med       Date:  2019-12-06       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.